We characterized the viral dynamics of human immunodeficiency virus (HIV) type 1-infected adolescents
namic model and estimated the first phase decay rate to be 0.49 copies/day with a half-life of 1.55 days under ritonavir monotherapy. In addition, the half-life of free virions was estimated to be 6 h. Perelson et al. [4] further proposed a model for a longer period of treatment from which a biphasic decay of plasma HIV-1 RNA was observed under a combination therapy of nelfinavir (NFV), zidovudine (ZDV), and lamivudine (3TC). They reported the first phase decay slope as 0.7 copies/day with a half-life of 1.1 days (faster than their earlier estimates under monotherapy regimens) and the second phase decay slope as 0.066 copies/day with a half-life of 2 weeks. They argued that the first-phase decay rate may represent the turnover rate of shortlived, productively infected cells and that the secondphase decay rate may represent the turnover rate of long-lived, infected cells. They estimated the half-life of latently infected cells as 8.5 days, using peripheral blood mononuclear cell infectivity data. Wu et al. [5] reported the viral dynamic results from a study developed by AIDS Clinical Trials Group (ACTG 315), and the decay rates of the 2 phases were estimated as 0.47 (half-life, 1.5 days) and 0.04 (half-life, 17.2 days) copies/day, respectively, under treatment with ritonavir for the first 9 days and with ZDV and 3TC added on day 10. They suggested that the interpatient variation in viral decay rates was large. In a pediatric ACTG study (PACTG 356), Luzuriaga et al. [6] presented results of viral dynamics in infants (!2 years) perinatally infected with HIV-1 and receiving ZDV/3TC/nevirapine, which showed similar results to adults. For example, in the first cohort of that study, the 2 phase decay rates were reported as 0.56 (half-life, 1.2 days) and 0.04 (half-life, 17.2 days) copies/day, respectively. However, no data have been reported on the viral dynamics of adolescents infected through risk behavior and who are receiving highly active antiretroviral therapy (HAART).
The potency of an antiretroviral regimen should be assessed soon after the initiation of therapy, so that a less potent regimen can be stopped early, to avoid the development of drug resistance and virus rebound. It has been reported that initial viral decay rates, estimated from viral dynamic models, may be good indicators of the potency of antiretroviral regimens [7] [8] [9] . However, baseline indices and host factors that may affect initial viral decay rates and the value of viral decay rates in predicting longer-term virological responses have not been well established [5, [10] [11] [12] [13] [14] . In PACTG 381, we collected viral dynamic data on 115 evaluable HIV-1-infected adolescents and studied the relationship of viral dynamic indices with baseline host factors and week 24 virological responses.
SUBJECTS, MATERIALS, AND METHODS
Clinical trial and treatment. This protocol was reviewed and approved by the institutional review boards at each site. Informed consent was obtained from each volunteer patient in accordance with guidelines of the US Department of Health and Human Services and those of the authors' institutions. PACTG 381 was conducted at 28 clinical sites in the United States. HIV-1-infected adolescents aged 8-22 years who had not acquired HIV infection by the perinatal route and were either treatment naive or had received monotherapy were eligible to participate in the study. Patients were excluded if they had documented perinatal transmission or transfusion-related transmission of HIV infection during the perinatal period or had received HIV immunotherapy, including HIV vaccines. Study subjects initiated a HAART regimen, defined as a minimum of 3 drugs, at least 1 of which had to have been either a protease inhibitor or efavirenz (EFV). The most common initial regimens were 3TC/ZDV/EFV (48%) and 3TC/ZDV/ NFV (37%). The remaining 15% of subjects initiated a variety of other HAART regimens. Our results will be summarized using these 3 categories of regimen.
HIV-1 RNA polymerase chain reaction and immunological assays. Blood samples were obtained from patients for quantitative analysis of plasma HIV-1 RNA before entry, at entry (day 0, the day of starting treatment), days 1, 2, 7, 10, and 14, and weeks 4, 8, 12, 16 , and 24 and then every 12 weeks. In a revised version of the study protocol, the day 1 measurement was dropped, and additional measurements at days 4 and 21 were included. The plasma samples were assayed using the Standard Roche Amplicor Assay (Roche Molecular Systems) to quantitate plasma HIV-1 RNA. Copy numbers of each plasma sample were calculated on the basis of the optical density readout. The lower limit of quantitation (LLQ) was 400 copies/mL. The lower limit of detection (LLD) was a 0.2 optical density readout from the most concentrated sample. The assays were performed in PACTG virology laboratories certified in the performance of the assay by Roche Molecular Diagnostics as well as the Virology Quality Assurance Program of the PACTG [15, 16] . Virological success was determined using the LLD, because a qualitative determinate was needed-that is, a detectable or an undetectable level of virus. A positive virological response to treatment (virological responder) at week 24 was determined as an OD of !0.2 at weeks 12 and 16 or an OD of !0.2 at week 16 with a 1 log 10 copies/mL decrease from baseline to week 12 and an OD of !0.2 between weeks 16 and 24 (note that an OD of !0.2 is approximately equivalent to HIV-1 RNA level !100 copies/mL). All other subjects with virus load data available were classified as nonresponders.
Cell phenotypes were determined in whole blood using dualand 3-color flow cytometry on an Epics Elite Flow Cytometer, as described elsewhere [17] . Monoclonal antibodies were from the Becton Dickinson Immunocytometry System. Mathematical models and statistical methods. A nonlinear mixed-effects biphasic viral dynamic model [18, 19] was used to estimate population and individual viral decay rates, according to the following formula:
where V i (t) is HIV-1 RNA copies/mL plasma at treatment time t for the ith subject. The viral decay rates for the ith subject are and , where d 1 and
population decay rates for the 2 viral decay phases and b 1i and b 2i are random effects with mean zero that quantify the between-subject variation of viral decay rates. Parameters P p 1i and are macroparameters, with
being baseline virus load at time . The exp (P ) + exp (P )
HIV-1 RNA measurement error (on the log 10 scale) i (t) is a mean zero white-noise process. The nonlinear mixed-effects model approach is preferable to the standard nonlinear leastsquares method [18] [19] [20] .
To fit the biphasic viral dynamic model, we only included HIV-1 RNA data from day 0 to week 4 (with a 2-week window) during treatment, because the virus load may fall below the LLD or viral rebound may occur after 4 weeks. Also, the viral dynamic model is valid only for the early stage of treatment [4, 18] . If there was a viral rebound (an increase from the previous virus load measurement) within 4 weeks for a patient, we excluded the rebound data. If the HIV-1 RNA level fell below the LLQ (BLLQ) within 4 weeks for a patient, we only included the first BLLQ value, because imputing 11 BLLQ value can create an artificial leveling-off effect during the secondphase decay. The SIMPLE method introduced by Ding and Wu [19] was used to fit the viral dynamic model. The model fitting was implemented using statistical software Splus (function NLME; Insightful). The grid-search method was used to find the best initial values for the model-fitting algorithm.
Wilcoxon rank sum tests were applied to the empirical Bayesian estimates of individual viral decay rates for between-group comparisons (see [20] for a justification of this method). Spearman's rank correlation test was used to identify significant correlations between viral decay rates and other factors [12] . Univariate and multivariate regression analyses were also used to confirm the correlation results. All P values were 2-sided and were not adjusted for multiple testing.
RESULTS
One hundred twenty subjects enrolled in the study and started their initial HAART regimens. Of the 120 subjects, 115 were included in the viral dynamic analysis. One subject had no virus load measurements. Four subjects had no initial viral decline after starting treatment; thus, these 4 subjects' virus load data did not fit to the viral decay model and were ineligible for viral dynamic analysis. Because of early viral rebound, early dropout, falling below detection early, and other reasons, 60% of subjects in the study did not have the data on the second phase (no viral decay data after week 2). Thus, the secondphase decay rates for individual subjects may not be reliable. Our analysis and report will therefore focus on the first-phase decay rates. Baseline characteristics for 115 eligible subjects were similar to those of all enrolled subjects. Of the 115 eligible subjects, the youngest patient was 12 years old, and the oldest was 22 years old (5 subjects were 12-14 years old, 33 were 15-17 years old, and 77 were 18-22 years old). Most of the subjects (81 [70%] of 115) were black non-Hispanic, 25 (22%) were Hispanic, and 9 (8%) were white non-Hispanic. Most of the subjects (98 [82%]) had been infected through sexual contact, 5 had been infected through sexual abuse, 1 had been infected by injection drug use, 14 reported multiple risk factors, and 2 had an unknown source of infection. ). A regression analysis con-P p .72 firmed that treatment assignment was a significant predictor for phase 1 viral decay rates (d 1 ).
Estimates of viral decay rates are summarized for different age groups and ethnic groups in table 2. A 1-way analysis of variance (ANOVA) showed that the age effect on phase 1 viral decay rates was significant ( ). This result was margin-P p .033 ally confirmed by a univariate regression analysis (treating age as a continuous covariate). According to the results of an ANOVA analysis, there was a marginally significant difference among race/ethnicity groups ( ). P p .054 Predictors for viral decay rates. Figure 2 shows + ) CD8 T lymphocytes, age, and sex (data not shown). In addition, the univariate regression analyses identified that the age of patients was negatively correlated with phase 1 viral decay rates with a marginal significance (P p ), which is consistent with the ANOVA results, which in-.050 dicated that patients in the younger group (12-14 years) had higher phase 1 viral decay rates than the older groups. Multivariate regression analyses (including the covariates baseline HIV-1 RNA levels, baseline CD4
+ and CD8 + cell counts, age and sex of patients, and treatment assignment) indicated that baseline HIV-1 RNA levels and treatment assignment were significant predictors for phase 1 viral decay rates ( and P ! .001 , respectively). In the multivariate regression analyses, P p .007 age and race/ethnicity were not significant.
We observed a very strong correlation ( ; ) r p 0.89 P ! .001 between week 1 virus load reduction and phase 1 viral decay NOTE. 3TC, lamivudine; EFV, efavirenz; HAART, highly active antiretroviral therapy; NFV, nelfinavir; ZDV, zidovudine.
rates ( figure 3 ). Note that the correlations of viral decay rates with virus load reduction from baseline to times before or after day 7 were weaker, as Ding and Wu [8] suggested on the basis of computer simulation studies. For instance, the correlation coefficient of phase 1 viral decay rates with virus load reduction from baseline to day 4 was , and that to day 10 was r p 0.60 in our study. The correlations of virus load reduction r p 0.86 at week 1 with baseline factors were also similar to that of phase 1 viral decay rates (data not shown). In multivariate regression analyses, when the week 1 virus load reduction was included, it replaced treatment assignment as a significant predictor ( ), in addition to baseline RNA levels, in the final (best) P ! .001 prediction model for phase 1 viral decay rates.
Relationship of viral decay rates to week 24 virological response. Among 115 evaluable subjects, 67 were classified as virological responders, and 46 were classified as nonresponders by the study team. Two subjects were not classified to either category because of missing data. We compared the viral decay rates between the virological responders and nonresponders using a Wilcoxon rank sum test. We found that the first-phase decay rates in responders (mean , ) were only 48 (52%) of 92 subjects were responders. The week 1 virus load reduction in the responder group was also higher ( , ) than that in the nonresponder group mean ‫ע‬ SD 1.52 ‫ע‬ 0.50 ( : ). However, the difference was not stamean ‫ע‬ SD 1.42 ‫ע‬ 0.44 tistically significant ( ). The univariate logistic regression P p .33 analyses showed that phase 1 viral decay rates and treatment assignment were marginally significant predictors for 24-week virological response ( and , respectively), but P p .056 P p .085 neither was significant in multivariate analyses.
DISCUSSION
PACTG 381, to our knowledge, is the largest viral dynamic study in HIV-infected individuals completed to date. From our study, the estimates of viral decay rates (in particular, the firstphase viral decay rates) in adolescents infected with HIV-1 through high-risk behavior and receiving HAART are com- parable to those in adults [4, 10] and vertically infected infants [6] who are treated with HAART but larger than those in adults who are treated with monotherapy [3, 5, 10] .
It is desirable to rapidly assess the potency and potential durability of an antiretroviral treatment after a new regimen is started. One possible indicator of potency is the viral decay rate, estimated from viral dynamic models, as suggested by Perelson and Nelson [7] and Ding and Wu [8] . Our results indicate that the 3TC/ZDV/EFV regimen is more potent (faster phase 1 viral decay rates) than 3TC/ZDV/NFV and other HAART regimens. This is consistent with the observation of higher rates of response (67%) in the patients who received the 3TC/ZDV/EFV regimen, compared with those (51%) who received the 3TC/ZDV/NFV regimen, although the difference was not statistically significant ( ). Robbins et al.
[21] P p .15 also reported that EFV-containing HAART regimens were more effective in delaying treatment failure than NFV-containing HAART regimens in treatment-naive HIV-1-infected adults. We suspect that the potency of EFV-containing regimens may be one of the major contributing factors for the effectiveness of the regimen. We also observed that the individuals with a faster phase 1 viral decay rate were more likely to have suppressed virus load at week 24, which suggests that the antiviral potency or early viral decay rates are predictive of longer-term virological response in this particular patient population with the treatment regimens studied. High virus load may increase the likelihood of viral mutations because of high viral replication rates, which suggests that it may be beneficial to rapidly suppress a high pretreatment virus load to a lower level using more aggressive regimens. Our observations seem to support this concept-the patients with faster viral decay rates (indicating that the regimen was more potent for these patients) were more likely to maintain longer-term viral suppression, although their baseline virus loads were likely to be higher.
Mueller et al. [11] reported that 1-week virological response (including viral dynamic parameters), in combination with knowledge of some pharmacological and immunological parameters, can provide a robust prediction of longer term (у12 weeks) virological responses in a study of 41 children who received ritonavir monotherapy for the first 12 weeks, after which ZDV and didanosine were added. However, Spector et al. [22] did not establish a relationship between early virological response and sustained virus suppression in another pediatric study (PACTG 382) of HIV-1-infected children aged 3-16 years who were naive to protease inhibitors and nonnucleoside reverse-transcriptase inhibitors and who were treated with EFV and NFV in addition to 1 or 2 nucleoside reverse-transcriptase inhibitors. In a study of protease inhibitor-naive HIV-1-infected adults who received NFV monotherapy with different dose levels for 8 weeks, Mittler et al. [13] reported that viral decay rates during the first 2-3 weeks were predictive of 8-week virological response, which was not surprising. However, Huang et al. [14] found that virological failure (rebound) was not predictable from the early virological response, in a metaanalysis of 4 ACTG studies (ACTG 343, 368, 359, and 398) with a mixture of different patient populations that included both treatment-naive patients and protease inhibitor-experienced patients receiving a variety of HAART regimens. Wu et al. [5, 23] also failed to detect a correlation between early viral dynamic parameters and long-term virological failure in 2 studies of protease inhibitor-naive HIV-1-infected adults receiving HAART regimens. In a combined analysis of several studies with HIV-1-infected children and adults who were naive to protease inhibitors and were treated with different monotherapies and HAART regimens, Polis et al. [24] reported that the early viral dynamics were predictive of longer-term (у12 weeks) virological response. These contradictory results may suggest that the role of early viral dynamics or responses as predictors of longer-term outcomes of antiretroviral treatment may depend on many factors, such as patient population and treatment regimens. If limited potency of a regimen plays a major role in treatment failure, we may be able to find a correlation between early viral dynamics (or early virological response) and a longer-term virological response. However, if other factors, such as the emergence of drug resistance, erratic adherence, interruptions in drug therapy, and pharmacokinetic problems, contribute more significantly to the virological failure of a regimen, the relationship between early viral dynamics and a longer-term response may not be identifiable.
Another important question that needs to be addressed from viral dynamic studies is what baseline host factors are predictive of the antiviral potency (viral decay rates). In the present study, Figure 1 . HIV-1 RNA data (dots) from 6 selected individuals and corresponding fitted trajectories using the NLME modeling approach we observed that baseline HIV-1 RNA levels were predictive of the viral decay rates. Baseline HIV-1 RNA levels were positively correlated with phase 1 viral decay rates. The positive correlation between baseline RNA levels and viral decay rates confirms the results of Notermans et al. [10] but differs from the results of Wu et al. [5, 12, 23] , in which a negative correlation between the first-phase viral decay rates and baseline RNA levels was observed. Some possible explanations for these correlations can be derived from a viral dynamic model proposed in Ding and Wu [8, 9] , but the biological mechanisms behind these correlations are still unclear. We speculate that the direction of the correlation may depend on many factors such as the potency of treatment regimens, pretreatment virus production: clearance ratio, and turnover rate of infected cells [9] .
Our findings on the difference in phase 1 viral decay rates for different age groups may suggest some differences in adherence among these age groups, although our self-reported adherence data could not provide enough evidence on this point (no correlation was observed between adherence and viral decay rates; data not shown). One reason is that the questionnaire may not be a reliable tool for adherence measurement in this patient population. However, it is possible that the 5 subjects aged 12-14 years had better adherence to their regimen under their caregiver's supervision, which resulted in a faster Figure 2 . The correlation between phase 1 viral decay rates and baseline HIV-1 RNA levels. The correlation coefficient and P value from Spearman's rank tests are given. 3TC, lamivudine; EFV, efavirenz; HAART, highly active antiretroviral therapy; NFV, nelfinavir; ZDV, zidovudine.
phase 1 viral decay than was seen in the older groups (ages 15-17 and 18-22 years). Differences in phase 1 viral decay rates for different ethnic groups may indicate that the antiviral potency may be affected by some other unidentified host factors such as host genetic differences. Note that the sample sizes of the 12-14 years age group and the white non-Hispanic group were small ( and respectively), and neither age nor n p 5 n p 9 race/ethnicity effects were significant in multivariate analyses with adjustment for baseline HIV-1 RNA levels and treatment assignment. Thus, we should interpret our results with caution. However, these interesting results warrant more studies on the effect of host factors on viral dynamics and antiviral responses.
We also observed a strong correlation between the first-phase viral decay rate (d 1 ) and week 1 virus load reduction from baseline (
). This finding suggests that the week 1 virus r p 0.89 load reduction could be used to replace more complex viral decay rates for the assessment of the potency of antiretroviral regimens. This simplification can avoid complicated viral dynamic model fitting and frequent clinical visits for HIV-1 RNA measurements, which eases the difficulty in the accrual of patients and implementation of viral dynamic studies. However, a larger sample size (number of subjects) may be needed to compensate for the power loss using the simpler marker (week 1 virus load reduction) [25] . In general, for phase 2 and 3 studies, the sample size is large enough that intensive viral dynamic studies may not be necessary, making a week-1 virus load reduction sufficient for the purpose of assessing the potency of a regimen. However, for a smaller study, an intensive viral dynamic study may be needed to provide more information, in particular for a new antiviral agent. In summary, the early viral dynamics or virus load reduction after initiating an antiretroviral therapy may be a good indicator for the potency of a regimen and thus can be used to assess the potency of new antiviral agents in a timely manner. 
